<DOC>
	<DOCNO>NCT00265148</DOCNO>
	<brief_summary>This placebo-controlled study evaluate effect rosiglitazone functional brain activity cognition patient mild moderate Alzheimer 's Disease ( AD ) .</brief_summary>
	<brief_title>Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Inclusion criterion : Is male , female meet one follow criterion : Postmenopausal female define menopause define &gt; 6months without menstrual period appropriate clinical profile , e.g . age appropriate , history vasomotor symptom . However indicate confirmed oestradiol FSH level consistent menopause ( accord local laboratory range ) . Women HRT treatment , confirm postmenopausal advise use contraception . ( See Appendix 4 ) Premenopausal female document ( medical report verification ) hysterectomy and/or bilateral oophorectomy reproductive status woman confirm follow hormone level assessment . Meets National Institute Neurological Communicative Diseases Stroke/Alzheimer 's Disease Related Disorders Association ( NINCDSADRDA ) criteria Alzheimer 's disease , regardless date diagnosis relative study entry date . ( See Appendix 5 ) Has Alzheimer 's disease status mild moderate , classify Mini Mental State Examination ( MMSE ) score 1626 inclusive screening . Is age &gt; /= 50 &lt; /= 85 year Prior current use medication corresponds criterion list Appendix 3 . Has ability comply requirement cognitive testing . Has permanent caregiver willing attend visit , oversee subject 's compliance protocolspecified procedure study medication , report subject 's status . ( Subjects live alone nursing home eligible ) . Has provide full write informed consent prior performance protocolspecified procedure ; unable provide inform consent due cognitive status , provision inform consent cognitively intact legally acceptable representative ( Where accordance local law , regulation ethic committee policy . ) Caregiver provide full write informed consent prior performance protocolspecified procedure . Exclusion criterion : Is unsuitable MRI scanning assess local preMRI questionnaire ( GSK review . ) Has history suffers claustrophobia . Is unable lie comfortably bed inside PET camera head field view least 60 minute assess physical examination medical history ( e.g . back pain , arthritis ) . Has history presence neurological medical condition may influence outcome analysis PET scan result . Examples condition include , limited stroke , traumatic brain injury , epilepsy space occupy lesion . History Type I Type II diabetes mellitus . Fasting plasma glucose level &gt; 126mg/dL ( &gt; 7.0mmol/L ) HbA1c &gt; 6.2 % . History clinical/laboratory evidence moderate congestive heart failure define New York Heart Association criterion ( class IIV ) ( See Appendix 6 ) . Ejection fraction &lt; /=40 % determine echocardiogram , abnormality echocardiography view investigator require investigation intervention , significant abnormality screen ECG ( accordance definition ) . Significant ECG abnormality purpose study . Detection follow abnormality render subject ineligible study : 1 . ECG heart rate &lt; 50 &gt; 100 bpm 2 . Any previously unrecognised sustain paroxysmal arrhythmia require intervention e.g . anticoagulation , cardioversion , antiarrhythmic agent , investigation etc . 3 . PR interval &gt; 0.3 , 2nd 3rd degree heart block , symptomatic bifascicular block , trifascicular block . 4 . Multifocal ventricular ectopy . 5 . Ventricular bigemini couplet , triplet etc . ECG abnormality permit entry study . A subject render ineligible presence follow abnormality : 1 . AF heart rate &lt; =90 subject receive appropriate antiplatelet anticoagulant therapy . 2 . 1st degree heart block ( PR &lt; =0.3 ) . 3 . Subjects pace rhythm ( information require subject implantable Cardiac Defibrillator ) . 4 . Atrial ectopic beat . 5 . Unifocal ventricular ectopic beat . 6 . Left right bundle branch block . 7 . Asymptomatice bifascicular block . 8 . Left ventricular hypertrophy . 9 . Q wave present suggest previous MI . 10 . Repolarisation abnormality History new cardiovascular event within last 6 month ( i.e . intervention , percutaneous coronary intervention , vascular surgery , acute coronary syndrome [ non Qwave myocardial infarction , Qwave myocardial infarction , unstable angina ) significant arrhythmia ; major intervention ( e.g . cardiac surgery angiography plus stenting ) schedule . History clinical laboratory evidence cerebrovascular disease ( stroke , transient ischaemic attack , haemorrhage ) , diagnosis possible , probable definite vascular dementia accordance National Institute Neurological Disorders Stroke , Association Internationale pour la Recherche et l'Enseignement en Neurosciences ( NINDSAIREN ) criterion ( See Appendix 8 ) . History evidence CNS disorder could interpret cause dementia : e.g . structural abnormality , epilepsy , infectious inflammatory/demyelinating CNS condition , Parkinson 's disease . Significant peripheral oedema time screen assessed Clinical Evaluation Oedema and/or Signs Congestive Heart Failure ( Appendix 14 ) History major psychiatric illness schizophrenia bipolar affective disorder , current depression ( score Hospital Anxiety Depression Scale ( HADS ) depression question &gt; 7 , See Appendix 9 ) . Systolic blood pressure &gt; 165 mmHg diastolic blood pressure &gt; 95 mmHG whilst receive optimal antihypertensive therapy accord local practice . Clinically significant anaemia ( i.e.haemoglobin &lt; 11g/dL male &lt; 10 g/dL female ) presence haemoglobinopathy would prevent accurate assessment HbA1c . Renal dysfunction , define creatinine clearance &lt; 30 ml/min ( calculate serum creatinine use CockcroftGault formula , See Appendix 10 ) . ALT , AST , total bilirubin , alkaline phosphatase &gt; 2.5 time upper limit normal laboratory range , history severe hepatobiliary disease ( e.g . hepatitis B C , cirrhosis ( ChildsPugh class B/C ) ) without enzyme elevation . Fasting triglyceride &gt; 12mmol/L Abnormal/positive result within past 12 month screen follow test : vitamin B12 ( &lt; /=200pg/mL ) , syphilis serology , thyroid stimulate hormone . History presence gastrointestinal , hepatic renal disease condition know interfere absorption , distribution , metabolism excretion drug . clinically relevant abnormality , medical psychiatric condition , , opinion investigator , make subject unsuitable inclusion study . Has donate &gt; /= ml blood within past 2 month . Use investigational agent within 30 day 5 halflives ( whichever longer ) prior screen visit . History alcohol abuse , drug abuse within past 6 month ( test positive drug abuse screen ) . Subject unable ( assistance , appropriate ) take study medication prescribe throughout study . History noncompliance prescribe medication , risk noncompliance study medication procedure . Subject immediate family member employee participate investigator participate site staff . Shows neurological abnormality MRI , opinion Principal Investigator would introduce additional risk factor , study procedure effect endpoint data . MRI scan conduct subject satisfy eligibility criterion . History bone marrow transplant Exhibits screening/baseline result consistent AD e.g . radiological finding , result cognitive test . Use tacrine within 30 day prior screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>rosiglitazone</keyword>
	<keyword>cognition</keyword>
	<keyword>cerebral glucose metabolism</keyword>
	<keyword>positron emission tomography ( PET )</keyword>
	<keyword>Alzheimer 's Disease</keyword>
</DOC>